TY - JOUR AU - Seoane-Vazquez, E. PY - 2008 DA - 2008// TI - Incentives for orphan drug research and development in the United States JO - Orphanet J Rare Dis VL - 3 UR - https://doi.org/10.1186/1750-1172-3-33 DO - 10.1186/1750-1172-3-33 ID - Seoane-Vazquez2008 ER - TY - JOUR AU - Tambuyzer, E. PY - 2010 DA - 2010// TI - Rare diseases, orphan drugs and their regulation: questions and misconceptions JO - Nat Rev Drug Discov VL - 9 UR - https://doi.org/10.1038/nrd3275 DO - 10.1038/nrd3275 ID - Tambuyzer2010 ER - TY - JOUR AU - Wellman-Labadie, O. AU - Zhou, Y. PY - 2010 DA - 2010// TI - The US orphan drug act: rare disease research stimulator or commercial opportunity? JO - Health Policy VL - 95 UR - https://doi.org/10.1016/j.healthpol.2009.12.001 DO - 10.1016/j.healthpol.2009.12.001 ID - Wellman-Labadie2010 ER - TY - JOUR AU - Braun, M. M. PY - 2010 DA - 2010// TI - Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years JO - Nat Rev Drug Discov VL - 9 UR - https://doi.org/10.1038/nrd3160 DO - 10.1038/nrd3160 ID - Braun2010 ER - TY - JOUR AU - Haffner, M. E. PY - 2006 DA - 2006// TI - Adopting orphan drugs—two dozen years of treating rare diseases JO - N Engl J Med VL - 354 UR - https://doi.org/10.1056/NEJMp058317 DO - 10.1056/NEJMp058317 ID - Haffner2006 ER - TY - JOUR AU - Haffner, M. E. AU - Whitley, J. AU - Moses, M. PY - 2002 DA - 2002// TI - Two decades of orphan product development JO - Nat Rev Drug Discov VL - 1 UR - https://doi.org/10.1038/nrd919 DO - 10.1038/nrd919 ID - Haffner2002 ER - TY - JOUR AU - Melnikova, I. PY - 2012 DA - 2012// TI - Rare diseases and orphan drugs JO - Nat Rev Drug Discov VL - 11 UR - https://doi.org/10.1038/nrd3654 DO - 10.1038/nrd3654 ID - Melnikova2012 ER - TY - JOUR AU - Rodriguez-Monguio, R. AU - Spargo, T. AU - Seoane-Vazquez, E. PY - 2017 DA - 2017// TI - Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? JO - Orphanet J Rare Dis VL - 12 UR - https://doi.org/10.1186/s13023-016-0551-7 DO - 10.1186/s13023-016-0551-7 ID - Rodriguez-Monguio2017 ER - TY - JOUR AU - Miller, K. a. t. h. l. e. e. n. L. AU - Lanthier, M. i. c. h. a. e. l. PY - 2016 DA - 2016// TI - Trends In Orphan New Molecular Entities, 1983–2014: Half Were First In Class, And Rare Cancers Were The Most Frequent Target JO - Health Affairs VL - 35 UR - https://doi.org/10.1377/hlthaff.2015.0921 DO - 10.1377/hlthaff.2015.0921 ID - Miller2016 ER - TY - JOUR PY - 2006 DA - 2006// TI - Reimbursement for cancer treatment: coverage of off-label drug indications JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2006.06.8940 DO - 10.1200/JCO.2006.06.8940 ID - ref10 ER - TY - STD TI - Orphan Drug Designations and Approvals. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/. Accessed 2 May 2018. UR - https://www.accessdata.fda.gov/scripts/opdlisting/oopd/ ID - ref11 ER - TY - STD TI - Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed 2 May 2018. UR - https://www.accessdata.fda.gov/scripts/cder/daf/ ID - ref12 ER - TY - JOUR AU - Hernandez, J. J. AU - Pryszlak, M. AU - Smith, L. AU - Yanchus, C. AU - Kurji, N. AU - Shahani, V. M. AU - Molinski, S. V. PY - 2017 DA - 2017// TI - Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics JO - Front Oncol VL - 7 UR - https://doi.org/10.3389/fonc.2017.00273 DO - 10.3389/fonc.2017.00273 ID - Hernandez2017 ER - TY - JOUR AU - DiMasi, J. A. AU - Grabowski, H. G. PY - 2007 DA - 2007// TI - Economics of new oncology drug development JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.0803 DO - 10.1200/JCO.2006.09.0803 ID - DiMasi2007 ER - TY - JOUR AU - Eckhouse, S. AU - Lewison, G. AU - Sullivan, R. PY - 2008 DA - 2008// TI - Trends in the global funding and activity of cancer research JO - Mol Oncol VL - 2 UR - https://doi.org/10.1016/j.molonc.2008.03.007 DO - 10.1016/j.molonc.2008.03.007 ID - Eckhouse2008 ER -